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Simple Summary: Primary aldosteronism is a common form of endocrine hypertension often
caused by a hyper-secreting tumor of the adrenal cortex called an aldosterone-producing adenoma.
Metabolic reprogramming plays a role in tumor progression and influences the tumor immune
microenvironment by limiting immune-cell infiltration and suppressing its anti-tumor function. We
hypothesized that the development of aldosterone-producing adenomas involves metabolic adapta-
tions of its component tumor cells and intrinsically influences tumor pathogenesis. Herein, we use
state-of-the-art computational tools for the comprehensive analysis of array-based gene expression
profiles to demonstrate metabolic reprogramming and remodeling of the immune microenvironment
in aldosterone-producing adenomas compared with paired adjacent adrenal cortical tissue. Our
findings suggest metabolic alterations may function in the pathogenesis of aldosterone-producing
adenomas by conferring survival advantages to their component tumor cells.
Abstract: Aldosterone-producing adenomas (APAs) are characterized by aldosterone hypersecretion
and deregulated adrenocortical cell growth. Increased energy consumption required to maintain
cellular tumorigenic properties triggers metabolic alterations that shape the tumor microenvironment
to acquire necessary nutrients, yet our knowledge of this adaptation in APAs is limited. Here, we
investigated adrenocortical cell-intrinsic metabolism and the tumor immune microenvironment of
APAs and their potential roles in mediating aldosterone production and growth of adrenocortical cells.
Using multiple advanced bioinformatics methods, we analyzed gene expression datasets to generate
distinct metabolic and immune cell profiles of APAs versus paired adjacent cortex. APAs displayed
activation of lipid metabolism, especially fatty acid β-oxidation regulated by PPARα, and glycolysis.
We identified an immunosuppressive microenvironment in APAs, with reduced infiltration of CD45+
immune cells compared with adjacent cortex, validated by CD45 immunohistochemistry (3.45-fold,
p < 0.001). APAs also displayed an association of lipid metabolism with ferroptosis and upregulation
of antioxidant systems. In conclusion, APAs exhibit metabolic reprogramming towards fatty acid
β-oxidation and glycolysis. Increased lipid metabolism via PPARα may serve as a key mechanism
to modulate lipid peroxidation, a hallmark of regulated cell death by ferroptosis. These findings
highlight survival advantages for APA tumor cells with metabolic reprogramming properties.
Keywords: adaptive metabolism; adrenal gland; conn adenoma; fatty acid metabolism; ferroptosis;
hyperaldosteronism; metabolic reprogramming; β-oxidation; PPARα; tumor microenvironment
1. Introduction
Primary aldosteronism (PA) is the most frequent secondary cause of hypertension
characterized by the overproduction of aldosterone relatively autonomous of the renin-
angiotensin system. PA is generally classified into unilateral and bilateral forms, which
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determine the surgical or pharmacological treatment of the disease [1]. The surgical man-
agement of unilateral PA has made available, as a side effect, tissue sample specimens for a
wide range of scientific studies. Histopathology shows that the surgically removed adrenals
mainly display an aldosterone-producing adenoma (APA) with somatic mutations in a few
genes that cause constitutive aldosterone production [2–5]. The variants usually occur in
genes that encode ion channels or ATPases and function in the regulation of cellular ion
homeostasis [6]. Of these, the KCNJ5 inwardly rectifying potassium channel (also called
GIRK4) displays the highest prevalence of variants in most reported populations. Further-
more, in vivo observations and in vitro findings suggest that KCNJ5 mutations are likely
to also cause cell proliferation [7–9]. The role of somatic mutations in constitutive aldos-
terone production is well defined, but many other mechanisms may modulate aldosterone
production from APAs [10–15]. Regulated forms of cell death, including apoptosis [16] and
ferroptosis [17], have also been implicated in the pathogenesis of APAs.
Metabolic reprogramming has a well-characterized role in cancer progression [18].
Increasing evidence suggests that tumor cells must modify their metabolism in response to
their elevated energy requirements [19], and metabolic adaptations have been described in
many types of cancers [20–22]. Of note, tumor cells undergo metabolic reprogramming
that may modify the tumor microenvironment (TME) to fulfill the demands of biosynthesis
and growth [23]. Tumor-infiltrating immune cells also rely on nutrients in the TME,
and metabolic competition between tumor cells and infiltrating immune cells hamper
or eliminate the anti-tumor immune response [23,24]. Furthermore, the high metabolic
activity of tumor cells can generate metabolites (e.g., adenosine, kynurenine, and acidosis)
that may accumulate to toxic concentrations, target immune suppressive cells and inhibit
their function [25–27]. For instance, increased glycolysis in cancer cells (the Warburg
effect) produces lactate that acidifies the TME and interferes with immune-cell effector
function [28].
Because APAs are hormone-producing adenomas, an increased metabolic demand
compared with adjacent tissue would be expected to sustain aldosterone hypersecretion.
In this study, we investigated metabolic differences between APAs and paired adjacent
cortical tissue to investigate mechanisms of the TME to support the development and
progression of an APA.
2. Materials and Methods
2.1. Data Preprocessing
We analyzed microarray gene expression data from GSE64957 [29] and GSE60042 [30]
from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/
access date for GSE64957 and GSE60042: 1 January 2021 and 5 April 2021, respectively).
GSE64957 comprised a data set from 13 APAs with corresponding paired zona glomerulosa,
and zona fasciculata samples (7 APAs with a KCNJ5 mutation and 6 APAs with no mutation
detected). GSE60042 comprised 7 APAs and paired adjacent adrenal cortex tissue samples.
GSE64957 Affymetrix microarray raw data were processed using the robust multichip
average (RMA) algorithm with R package oligo for background adjustment, quantile
normalization, log-transformation, and Combat function of R package sva (surrogate
variable analysis) was used for batch correction. The expression matrix of GSE60042 was
extracted from series matrix files downloaded from the GEO database using the GEOquery
package, followed by standardization using the normalize Between Arrays function of the
limma R package. The gene expression datasets were translated into commonly used gene
symbols for further analyses.
The R package “limma” was used to clarify differentially expressed genes among
paired groups; differentially expressed genes with adjust p < 0.05 and log2 fold change (FC)
(log2FC) >1 were selected for further functional enrichments.
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2.2. Patient Samples
Resected adrenal samples for histology and immunohistochemistry analyses were
from patients diagnosed with unilateral primary aldosteronism following European Soci-
ety of Hypertension guidelines [31,32] at the Medizinische Klinik IV, Klinikum Ludwig-
Maximilians-Universität München, Munich, Germany, in accordance with local criteria
for adrenal venous sampling [33]. These APAs comprised 6 with a KCNJ5 mutation and
6 without KCNJ5 mutations (2 CACNA1D, 2 ATP1A1, and 2 with no mutation detected).
These patients gave written informed consent for use of biomaterial for medical research in
accordance with the local ethics committee.
2.3. Functional Enrichments
To identify biological processes and pathway enrichment associated with differentially
expressed genes, we used the gene set enrichment analysis (GSEA) method based on Gene
Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), HALLMARK and
Reactome gene sets from MSigDB database with the clusterProfiler package of R. The online
tools of Metascape® (https://metascape.org access data: 11 April 2021) [34] and g:profiler
(https://biit.cs.ut.ee/gprofiler access data: 21 April 2021) [35] were also used to identify
pathway interactions, and protein–protein interaction networks, and to comprehensively
understand the biology of differentially expressed genes using different independent
knowledge bases (e.g., WikiPathways) to summarize the function of identified genes.
2.4. Determination of Tumor Immune Microenvironment and Immune Cell Infiltration Patterns
To assess tumor immune microenvironments, the “Estimation of Stromal and Immune
cells in Malignant Tumors using Expression data” (ESTIMATE) algorithm [36] was used to
quantify the infiltrating immune cell level (immune score) and stromal content (stromal
score) for each sample, using gene expression signatures.
To further evaluate the immune characteristics of APA and adjacent zona glomerulosa
cells, single sample GSEA (ssGSEA) [37] analysis was performed to identify the relative
proportions of 28 immune cell types in the TME based on the feature gene panels for each
immune cell type [38,39]. In addition, the Microenvironment Cell Populations-counter
(MCP-counter) algorithm [40,41] was used to calculate stromal cell abundance, including
endothelial cells and cancer-associated fibroblasts.
2.5. Identification of Ferroptosis-Related, Immune-Related, and Reactive Oxygen Species
(ROS)-Related Genes
The corresponding ferroptosis-related gene list was downloaded from FerrDb [42].
In total, we identified 259 ferroptosis-related genes, including 108 drivers, 69 suppressors,
and 111 markers. The immune-related gene lists were obtained from ImmPort (https:
//www.immport.org/resources access data: 21 December 2020). The ROS-related gene
list was collected from the GeneCards database (https://www.genecards.org/ access data:
4 April 2021) using the term “reactive oxygen species”, and only genes with a relevance
score >7 were considered. All significantly differentially expressed genes were set at adjust
p-value < 0.05 and |log2FC| > 1.
2.6. Immunohistochemistry
Formalin fixed paraffin-embedded sections of APA tissue were incubated with anti-
CD45 primary antibody (#13917; Cell Signaling Technology, Danvers, MA, USA) at 4 ◦C
overnight. Immunohistochemistry staining was performed using ZytoChem Plus HRP
Polymer kit (Zytomed, Berlin, Germany) following the manufacturer’s instructions and
quantified with QuPath (v.0.2.3, University of Edinburgh, Edinburgh, UK) using the posi-
tive cell detection feature with empirical parameters.
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2.7. Cell Line and Culture Conditions
Human adrenocortical (HAC15) cells (a kind gift from Professor William E. Rainey,
University of Michigan, Ann Arbor, MI, USA) were cultured in Dulbecco’s Modified
Eagle/F12 medium with L-glutamine containing 10% (v/v) cosmic calf serum, 1% antibiotic-
antimycotic, 1% insulin-transferrin-selenium, and 50 mg/mL gentamycin at 37 ◦C and
5% CO2.
2.8. Cell Viability Assay
HAC15 cells (4 × 104 per well) were seeded on 96-well plates for 24 h and then treated
with etomoxir (E1905, Sigma-Aldrich, St.Louis, MO, USA). Cell viability was measured
using WST-1 assay according to the manufacturer’s instructions (Roche Diagnostics GmbH,
Mannheim, Germany). Cells without etomoxir treatment were used as a control.
2.9. Statistics
R software (version 4.0.3, Vienna, Austria) and GraphPad Prism 8.0 (GraphPad Soft-
ware Inc., San Diego, CA, USA) were employed for figures generation and statistical
analyses. Differences between the two groups were analyzed through paired t-test or
paired Wilcoxon test, whereas Kruskal–Wallis test or One-way ANOVA was performed
between groups. The statistically significant level was set as p < 0.05.
3. Results
3.1. Transcriptome Defined Metabolic Reprogramming towards Fatty Acid β-Oxidation and
Glycolysis in APAs
Transcriptome data from GSE60042 were used to analyze the biology of differentially
expressed genes in APAs versus paired adjacent adrenal cortex. The top upregulated gene
sets were related to oxidative phosphorylation (Figure 1A) consistent with a proteomic
analysis of APAs [43].
Transcriptome data from GSE64957 were used to evaluate potential metabolic differ-
ences between APAs and paired adjacent zona glomerulosa. Alterations in transcriptome
signatures related to metabolic synthesis were distinguished, with striking gene set en-
richments in APAs of oxidative phosphorylation, fatty acid metabolism, and glycolysis
(Figure 1A,B). Reactome gene sets demonstrated that the most significantly upregulated
signaling pathways in APAs were mitochondrial fatty acid β-oxidation and peroxisome
proliferator-activated receptor-α (PPARα) (Figure 1C). These data suggest that APAs may
oxidize fatty acids as an energy source for tumor growth and/or steroidogenesis through
PPARα signaling. We explored potential crosstalk between these signaling pathways
using Metascape analyses with ClueGo, a Cystoscope plug-in. These network analyses
highlighted that most signaling pathways involved aspects of lipid biology at the core
of the pathogenesis of APAs. Furthermore, we demonstrated a functional link between
lipid biology and ferroptosis. This is relevant because adrenocortical cells have previously
been shown to be highly sensitive to cell death by ferroptosis due to the inhibition of
glutathione biosynthesis (Figure 2A) [17,44,45]. Of note, the ferroptosis suppressor gene
coding for glutamate-cysteine ligase catalytic subunit (GCLC) and the gene coding for
stearoyl-CoA desaturase (SCD) are highly expressed in APAs compared with adjacent
zona glomerulosa (Figure 2C). In addition, protein–protein interaction network analysis
of differentially expressed genes revealed an upregulation of hub genes involved in gly-
colysis/gluconeogenesis using the Molecular Complex Detection algorithm (Figure 2B).
Collectively, our evidence indicates that metabolic reprogramming towards fatty acid
β-oxidation and glycolysis may confer some metabolic advantage to the APA microenvi-
ronment that may sustain tumor cell growth and aldosterone overproduction.
The GSE64957 data set was used to evaluate potential metabolic differences between
APAs and paired adjacent zona fasciculata. Fatty acid β-oxidation was observed in adjacent
zona fasciculata relative to paired adjacent zona glomerulosa (Figure 1D). We further
analyzed the upregulated differentially expressed genes in APAs compared with adjacent
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zona glomerulosa and in paired zona fasciculata, compared with adjacent zona glomerulosa
(Figure 2D). APAs specifically overexpressed genes related to glycolysis/gluconeogenesis,
whereas genes that were exclusively upregulated in the paired adjacent zona fasciculata
were enriched in pathways related to lipid metabolism.
3.2. KCNJ5 Mutations and Metabolic Reprogramming
APAs with KCNJ5 mutations show an increased proliferative index compared with
other APAs [9]. We investigated if KCNJ5 mutated APAs display distinct metabolic features.
We showed that genes involved in glycolysis and lipid metabolism displayed enhanced
transcription in KCNJ5 mutated APAs relative to Wild type APAs (both normalized to their
adjacent zona glomerulosa) (Figure 2D).
3.3. Fatty Acid Oxidation Is Required for the Survival of Human Adrenocortical Cells
To further elaborate the functional role of fatty acid oxidation in human adrenal cells,
HAC15 cells were treated with etomoxir in culture, an inhibitor of fatty acid oxidation via
carnitine palmitoyltransferase-1 inhibition. Etomoxir significantly decreased cell viability
of HAC15 cells in a dose-s and time-dependent manner (Figure 3A,B), indicating that fatty
acid oxidation may support adrenocortical cell growth.




Figure 1. APAs undergo transcriptomic alterations toward increased fatty acid metabolism and glycolysis. (A) GSEA 
showing MSigDB hallmark of upregulated differentially expressed genes in APAs versus AAC (GSE60042) and adjacent 
ZG (GSE64957). Pathways in red indicate functions related to lipid metabolism and glycolysis. (B) Heatmap of the signif-
icant upregulated differentially expressed genes with p value < 0.05 for fatty acid metabolism in APAs compared with 
adjacent ZG. (C) GSEA plots showing Reactome pathways of lipid biological processes in APAs versus adjacent ZG. (D) 
GSEA plots showing Reactome pathways of mitochondrial fatty acid β-oxidation in ZF versus paired adjacent ZG. APA, 
aldosterone-producing adenoma; AAC, adjacent adrenal cortex; ZG, zona glomerulosa; ZF, zona fasciculata; NES, nor-
malized enrichment score; FDR, false discovery rate. 
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Figure 1. APAs undergo transcriptomic alterations toward increased fatty acid metabolism and glycolysis. (A) GSEA
showing MSigDB hallmark of upregulated differentially expressed genes in APAs versus AAC (GSE60042) and adjacent
ZG (GSE64957). Pathways in red indicate functions related to lipid metabolism and glycolysis. (B) Heatmap of the
significant upregulated differentially expressed genes with p value < 0.05 for fatty acid metabolism in APAs compared
with adjacent ZG. (C) GSEA plots showing Reactome pathways of lipid biological processes in APAs versus adjacent ZG.
(D) GSEA plots showing Reactome pathways of mitochondrial fatty acid β-oxidation in ZF versus paired adjacent ZG.
APA, aldosterone-producing adenoma; AAC, adjacent adrenal cortex; ZG, zona glomerulosa; ZF, zona fasciculata; NES,
normalized enrichment score; FDR, false discovery rate.
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Figure 2. The interaction between lipid metabolism and ferroptosis, and the association of metabolic alterations with adjacent
adrenal cortical tissue and APA genotype. (A) Metascape functional enrichment analysis of upregulated differentially
expressed genes in APAs versus paired adjacent ZG (GSE64957). One node per enriched term, colored by cluster ID. Node
size indicates the number of differentially expressed genes i volved in the enriched term. (B) i –protei network
using Molecular Complex Detection (MCODE) algorithm. Red fonts represent the core genes of the network involved in
the glycolysis/gluconeogenesis pathway. (C) Heat map of ferroptosis-related upregulated differentially expressed genes
grouped as driver and suppressor in APAs compared paired adjacent ZG. (D) Venn diagrams showing the number of
unique and overlapping upregulated differentially expressed genes from APAs and adjacent ZF of those APAs to paired
adjacent ZG comparisons, and from KCNJ5 mutated APAs and APAs without mutations (Wild type) to their adjacent ZG
comparisons. Top pathways in which the distinct differentially expressed genes from APAs, adjacent ZF, KCNJ5-mutated
APA, and APA without mutations (Wild type), respectively compared to paired adjacent ZG, using g:profiler online tool.
APA, aldosterone-producing adenoma. AAC, adjacent adrenal cortex; ZG, zona glomerulosa; ZF, zona fasciculata; DEGs,
differentially expressed genes; NES, normalized enrichment score; FDR, false discovery rate.
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Figure 3. Inhibition of fatty acid oxidation induces cell death in human HAC15 cells. (A) Repre-
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Figure 3. Inhibition of fatty acid oxidation induces cell death in human HAC15 cells. (A) Represen-
tative images of the effects of etomoxir in HAC15 cells in 6-well plate for 72 h. Scale Bar: 50 µm.
(B) Cell viability in HAC15 cells treated with increasing concentration of etomoxir (25–200 µM) for
24 h, 48 h, and 72 h. Data are presented as mean ± s.d., One-way ANOVA; ** p < 0.01, *** p < 0.001.
3.4. Immune Phenotype Alterations in APAs
Dysregulation of tumor cell metabolism is known to contribute to immune evasion
within the TME. Therefore, we investigated the effect of metabolic reprogramming of the
TME on tumor-infiltrating immune-cell populations in APAs and adjacent adrenal cortical
tissue. We used GSEA to screen for downregulated differentially expressed genes in APAs
versus paired adjacent adrenal cortex and identified a vast number of immune-related
pathways that were relatively increased in adjacent adrenal cortex, including inflammatory
response, interferon-gamma response, and IL6 JAK STAT3 signaling (Figure 4A). Further
analysis using the ESTIMATE algorithm to predict immune states revealed a statistically
significant decrease of the immune and stromal score in APAs compared with paired
adjacent adrenal cortex (p < 0.01, paired t test, Figure 4C). Collectively, APAs had a higher
proportion of tumor cells. To validate these findings, we performed immunohistochemistry
analysis of the surface protein CD45, a common marker of immune cells, on 12 formalin-
fixed paraffin embedded APA samples with attached adjacent adrenal cortex (Figure 4B).
The density and frequency of CD45+ cells per mm2 were significantly lower in APAs
relative to the adjacent adrenal cortex (3.45-fold, p < 0.001, paired Wilcoxon test, Figure 4D),
which included 6 KCNJ5-mutated APAs and 6 APAs without KCNJ5 mutation. This is
consistent with previous studies reporting sparse or no immune-cell infiltration within
APAs compared to cortisol-producing adenoma [46]. These findings support the concept
of tumor cells within the TME of APAs evading immune surveillance.
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We used a similar approach to assess tumor-infiltrating immune cells of APAs, 
paired adjacent zona fasciculata, and adjacent zona glomerulosa (Figure 5A–C). APA had 
Figure 4. Spatial organization of tumor infiltrating immune cells in APAs versus paired adjacent adrenal cortex (AAC).
(A) GSEA showing MSigDB hallmark of downregulated differentially expressed genes in APAs versus AAC (GSE60042).
Pathways in red indicate functions related to immune response. (B) CYP11B2 and CD45 im unohistochemistry staining.
The border of PA is defined by the CYP11B2 i unohistochemistry. Scare bar: 100 µm. (C) ESTIMATE algorithm showing
the distribution of ImmuneScore, StromalScore in AP s versus AAC. ** p < 0.01 by paired t test. (D) CD45+ immune cell
densit a positive percentage between AP s and AAC. *** p < 0.001 by paired Wilcox test. APA, aldosterone-producing
adenoma; AAC, adjacent adrenal cortex; NES, normalized enrichm t score.
We used a similar approach to assess tumor-infiltrating immune cells of APAs, paired
adjacent zona fasciculata, and adjacent zona glomerulosa (Figure 5A–C). APA had fewer
CD45+ immune cells compared with the adjacent zona glomerulosa and adjacent zona
fasciculata, suggesting an immunosuppressive microenvironment at the local site of APA.
CD45+ immune cells in the adjacent zona fasciculata showed higher levels compared
to those in adjacent zona glomerulosa, indicating that fatty acid β-oxidation may not
contribute to the immunosuppressive properties of APA.
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ZG. Overview of CD45 image: scale bar 2 mm. Deep zoom images: scare bar 100 µm. APA, aldosterone-producing ade-
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3.5. Distinct Immune Microenvironment Landscapes in APAs vs. Paired Adjacent Zona 
Glomerulosa 
To further explore differences in the composition of immune cells of APAs and 
paired adjacent zona glomerulosa, we performed ssGSEA using the MCP-counter algo-
rithm, a method to profile fractions of immune cells by deconvolution of gene expression 
data, as shown in a heatmap (Figure 6A). Notably, principal component analysis showed 
Figure 5. Spatial organization of tumor-infiltrating immune cells in APAs. Tumor-infiltrating immune cells in APAs
were determined versus adjacent zona glomerulosa (ZG), and adjacent zona fasciculata (ZF). (A) GSEA showing MSigDB
hallmark of downregulated differentially expressed genes in APAs versus adjacent ZG (GSE64957). Pathways in red indicate
functions related to immune response. (B) ESTIMATE algorithm showing the distribution of ImmuneScore, StromalScore
among APAs, adjacent ZG, and adjacent ZF. * p < 0.05, ** p < 0.01, *** p < 0.001 by paired Wilcox test. Kruskal–Wallis
test was used between groups. (C) Immunohistochemistry of H&E and CD45 staining among APA, adjacent ZF, and
adjacent ZG. Overview of CD45 image: scale bar 2 mm. Deep zoom imag s: scare bar 100 µm. APA, aldosterone-producing
adenoma; ACC, adjacent adrenal cortex; GSEA, g n s t enrichment analy is; NES, normalized enrichment score; Z , z
glo erulosa; F, zona fasciculata.
3.5. Distinct I une icroenviron ent Landscapes in P s vs. Paired djacent Zona
Glomerulosa
To further explore differences in the composition of immune cells of APAs and paired
adjacent zona glomerulosa, we performed ssGSEA using the MCP-counter algorithm, a
method to profile fractions of immune cells by deconvolution of gene expression data,
as shown in a heatmap (Figure 6A). Notably, principal component analysis showed two
distinct clusters of tumor-infiltrating immune cells of the TME (APAs vs. paired adjacent
zona glomerulosa) (Figure 6B). Further, we observed decreased anti-immune cells (e.g.,
activated and central memory CD4 T cells, effector memory CD8 T cells, and nature killer
cells) and increased pro-immune cells (immature dendritic cells) (Figure 6C–F).
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3.6. Functional Characterization of Immune-Related Differentially Expressed Genes in APAs
To classify immune-related genes, we intersected the whole dataset of differentially
expressed genes with immune-related genes from ImmPort. A total of 31 differentially
expressed immune-related genes were identified; 9 of these 31 were upregulated and the
remaining 22 genes were downregulated in APAs versus paired adjacent zona glomeru-
losa (Figure 7A). GO analysis determined downregulated genes related to the immune
response were enriched in the pathways related to “cellular response to oxidative stress”
(Figure 7B), suggesting that oxidative stress may elicit an inflammatory response in the
adjacent zona glomerulosa.
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3.7. Enhanced Anti-Oxidative Response Pathways in APAs
Our analyses indicate that adjacent zona glomerulosa are challenged with increased
oxidative stress compared to cells of APAs. To investigate the function of ROS within
the context of APA cells, we compared differentially expressed genes functionally related
to ROS in APAs vs. paired adjacent zona glomerulosa. We identified 22 upregulated
ROS genes and 40 downregulated ROS genes. KEGG analysis of the upregulated ROS
genes demonstrated upregulation of several metabolic pathways, including cholesterol
metabolism, peroxisome proliferator-activated receptor (PPAR) signaling, aldosterone
synthesis, and secretion (Figure 8B), suggesting that ROS may be involved in the regulation
of metabolism and/or affected by the intermediates of metabolic alterations. In contrast,
the most prominently altered processes of downregulated genes related to ROS were the
inflammatory response pathways (Figure 8D). Collectively, the link of ROS with metabolism
and the inflammatory response may suggest contributory biological mechanisms to the
pathogenesis of APAs.




Figure 8. Enhanced antioxidative response pathways in APAs. (A) GO analysis of GSEA showing heatmap of ROS-related 
pathways. Red and blue color indicate upregulated and downregulated pathways ordered by normalized enrichment 
score in APAs versus AAC, adjacent ZG, and adjacent ZF, respectively. Normalized enrichment score >0 means upregu-
lated pathways (Red), whereas normalized enrichment score <0 means downregulated pathways (Blue). Corresponding 
pathway enrichments are listed on the side. (B,D) indicate KEGG pathways of differentially expressed genes involved in 
ROS in APA versus adjacent ZG. Overexpressed ROS gene categories associated with metabolism pathways, whereas 
those downregulated ROS genes are associated with immune-response pathways. (C) The GPX4 gene expression between 
APAs, adjacent ZG, and adjacent ZF. ** p < 0.01 by paired Wilcoxon test. Kruskal–Wallis test was used between groups. 
APA, aldosterone-producing adenoma; AAC, adjacent adrenal cortex; ZG, zona glomerulosa; ZF, zona fasciculata; ROS, 
reactive oxygen species. 
To address how APAs accommodate high ROS levels and ameliorate oxidative stress, 
we summarized ROS-related pathways between APAs versus paired adjacent adrenal 
cortex, APAs vs. paired adjacent zona glomerulosa, and APAs versus paired adjacent 
zona fasciculata. In general, all adjacent tissues showed higher enrichment of genes in-
volved in ROS-related pathways such as “cellular response to oxidative stress” (Figure 
8A). Therefore, we postulated that adrenocortical tumor cells may increase antioxidant 
properties to counteract metabolic stress. Accordingly, we determined upregulation of the 
Figure 8. Enhanced antioxidative response pathways in APAs. (A) GO analysis of GSEA showing heatmap of ROS-related
pathways. Red and blue color indicate upregulated and downregulated pathways ordered by normalized enrichment score
in APAs versus AAC, adjacent ZG, and adjacent ZF, respectively. Normalized enrichment score >0 means upregulated
pathways (Red), whereas normalized enrichment score <0 means downregulated pathways (Blue). Corresponding pathway
enrichments ar li ted on the side. (B,D) indicate KEGG pathways of dif erentially expressed genes invol ed in ROS
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To address how APAs accommodate high ROS levels and ameliorate oxidative stress,
we summarized ROS-related pathways between APAs versus paired adjacent adrenal
cortex, APAs vs. paired adjacent zona glomerulosa, and APAs versus paired adjacent zona
fasciculata. In general, all adjacent tissues showed higher enrichment of genes involved in
ROS-related pathways such as “cellular response to oxidative stress” (Figure 8A). There-
fore, we postulated that adrenocortical tumor cells may increase antioxidant properties
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to counteract metabolic stress. Accordingly, we determined upregulation of the unfolded
protein response pathway in APAs (vs. adjacent zona glomerulosa) [47], which is an
adaptive mechanism to relieve endoplasmic reticulum stress and restore cellular metabolic
function, thereby promoting the survival of tumor cells. In addition, autophagy, a cellular
stress-response mechanism [48] that recycles key metabolites under metabolic stress and
promotes cellular adaptation to oxidative stress, was also enhanced in APAs. In addition,
glutathione peroxidase 4 (GPX4) mRNA levels, a key enzyme for antioxidant defense,
were higher in APAs among groups (Figure 8C). Together, these mechanisms ensure an
efficient alleviation of oxidative stress that APA cells encounter during excess aldosterone
production and abnormal proliferation.
4. Discussion
In this study we used advanced bioinformatics tools to comprehensively evaluate
the TME of APAs. We demonstrated that metabolic reprogramming towards fatty acid
β-oxidation and glycolysis is a general feature of APAs that may provide a metabolically
favorable environment for tumor growth. Furthermore, we showed an immunosuppressive
microenvironment in APA and diverse cellular components of the TME (e.g., immune and
stromal cells) between APAs and the adjacent zona glomerulosa.
We showed that lipid metabolism is highly associated with APA tumorigenesis.
Metabolism reprogramming enables tumor cells to sustain ATP generation for cell growth,
division, and survival. Notably, dysregulation of lipid metabolism has been demonstrated
as a prominent metabolic alteration in cancers [49]. In particular, increased β-oxidation of
stored lipids provides a source of NAPDH and ATP—approximately six times that of oxida-
tion of carbohydrates—through the oxidation of acetyl-CoA by the tricarboxylic acid (TCA)
cycle, thereby facilitating tumor progression [50]. Furthermore, NAPDH is critical for two
steps in steroidogenesis pathways in the adrenal gland: (1) the rate-limiting step for the
conversion of cholesterol to pregnenolone catalyzed by CYP11A1 and (2) the conversion of
deoxycorticosterone to aldosterone catalyzed by CYP11B2 [51,52]. Thus, elevated fatty acid
β-oxidation in APAs may stimulate aldosterone synthesis by the high metabolic activity of
NAPDH generation in mitochondria. In addition, our bioinformatics studies implied that
changes in lipid metabolism in APAs are regulated by PPARα. Previous studies reported
that transcriptional activation of PPARα regulates β-oxidation in tissues displaying high
energy consumption [53,54]. Consistent with our findings, a previous study demonstrated
that fenofibrate, a PPARα agonist, increased angiotensin II-independent CYP11B2 mRNA
expression and aldosterone production in human adrenocortical carcinoma H295R cells,
whereas a peroxisome proliferator-activated receptor-γ (PPARγ) agonist either had no ef-
fect or reduced aldosterone secretion [55]. These data indicate that high activity of fatty acid
β-oxidation induced by PPARα signaling may be crucial for excess aldosterone production.
Further to a role for fatty acid β-oxidation in APA pathogenesis, we reported that
glycolysis metabolism may also play a key role, especially in KCNJ5-mutated APAs. This
latter finding is consistent with a mass spectrometry imaging study that identified the acti-
vation of glycolysis pathways in APAs as well as in a subgroup of aldosterone-producing
micronodules [56] (previously known as aldosterone-producing cell clusters [57]). In con-
trast, a high-resolution mass spectrometry imaging map of the normal human adrenal
gland reported that glycolysis/gluconeogenesis was found to be significantly increased
in the medulla [58]. This finding is consistent with the concept that a metabolic switch
to glycolysis confers a selective advantage for tumor growth. However, the underlying
mechanism of such metabolic phenotypes is unclear. Of potential interest, lactate infusion
alone, or in combination with angiotensin II, results in increased aldosterone secretion from
rat zona glomerulosa cells [59]. Therefore, the precise relationship between glycolysis and
its metabolites and aldosterone production merits further investigation.
Our study showed the low tumor infiltrating CD45+ lymphocyte density in APAs.
Such a scenario is in line with previous reports showing sparse immune cell infiltration
using hematoxylin-eosin staining in APAs relative to cortisol-producing adenomas [46].
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This alteration in the TME may be accounted for by competition for nutrients in the TME,
and glycolysis intermediates forming an acidic microenvironment and thereby suppressing
immune activation [27,60]. Another potential mechanism is the promotion of immuno-
surveillance evasion by activated PPAR signaling [61]. PPARα exerts anti-inflammatory
activity, for example, and PPARα agonists mediate a variety of effects on the immune re-
sponse to reverse acute and chronic liver inflammation [54]. Consistently, PPARα-deficient
aged mice show a pro-inflammatory phenotype [62]. In addition, the PPARα agonist
fenofibrate caused a reduction in blood pressure, especially in salt-sensitive hypertensive
subjects [63], suggesting that PPARα may play a role in regulation of renin–angiotensin–
aldosterone system activity, and influence aldosterone secretion. This discrepancy may be
explained, however, by its dual influence on systemic and local tumor levels. Furthermore,
through expression–signature-based approaches, we observed low effector memory CD8 T
cell infiltration in APAs, which is in agreement with a previous study that demonstrated
decreased viability of effector T cells in a glucose-restricted medium in vitro [64]. These
data suggest that metabolic reprogramming towards glycolysis in APA may impose a
hypoglycemic environment, restrict glucose uptake by immune cells and therefore hamper
their function. In addition, a previous study showed that the distribution of mast cells is
more frequently visualized in the adjacent cortex of APAs [11], consistent with the high
mast cell infiltration in adjacent zona glomerulosa relative to APAs in our study.
Active steroidogenesis has been implicated in contributing to high ROS production
and oxidative stress, triggering cell death [65]. Our analyses demonstrated that the adjacent
cortex is challenged with increased oxidative stress compared to APAs, regions of high
steroidogenesis. Our finding of enhanced fatty acid β-oxidation in APAs may explain this
apparent paradox because it provides NAPDH, which may counteract ROS toxicity from
metabolic stress [66]. Furthermore, fatty acid β-oxidation is increased in zona fasciculata
relative to paired zona glomerulosa, likely because glucocorticoid production in normal
zona fasciculata produces significantly more cellular ROS than from aldosterone synthesis
in normal zona glomerulosa due to 40% of “leaky” electrons in the P450c11β (CYP11B1)
system [67]. This would require elevated fatty acid β-oxidation for protection of adreno-
cortical zona fasciculata cells from ROS. In addition, previous work demonstrated that
enhanced glycolysis can combat oxidative stress via increasing glutathione metabolism and
maintaining redox balance [68], a potential factor contributing to the larger tumor diameter
in APAs with KCNJ5 mutations. Additionally, our data showed an increased antioxidant
response via an enhanced unfolding protein response and autophagy [47,48], suggesting
that multiple mechanisms participate in the detoxification of ROS and aid adrenocortical
tumor cell survival.
It has been reported that adrenocortical cells are sensitive to ferroptosis-triggering
agents, such as RSL3, which can inhibit GPX4 activity [17,45]. Indeed, our data showed ele-
vated GPX4 expression in APAs compared with adjacent zona glomerulosa. Adrenocortical
tumor cells must boost their antioxidant capacity to counteract the lipid peroxidation and
oxidative stress induced by steroidogenesis to suppress cell death by ferroptosis. Although
studies into the molecular mechanisms underlying the adaptation of APA cells to high
ROS generation in the local tumor site to circumvent ferroptosis are not well defined, lipid
metabolism likely participates, and in particular fatty acid β-oxidation. This hypothesis
is partially supported by Kagan et al., who showed that etomoxir, an inhibitor of mito-
chondrial fatty acid β-oxidation, enhanced RSL3-induced ferroptosis in mouse embryonic
fibroblasts [69]. Further, PPARα activator can reduce lipid peroxidation [70]. Consider-
ing the known association of fatty acid β-oxidation with PPARα, PPARα activation may
feasibly regulate the susceptibility of adrenocortical cells to lipid peroxidation, a key charac-
teristic of ferroptosis, through β-oxidation. Furthermore, we observed increased SCD and
GCLC mRNA expression in APAs. Two key enzymes catalyze monounsaturated fatty acid
synthesis and biosynthesis of glutathione, which protect tumor cells against ferroptosis
inducers [71,72]. These exemplify the central hub role of metabolism reprogramming to
adapt to metabolic stress.
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This study reports a potential role of fatty acid oxidation in supporting adrenocortical
cell growth; however, further research is required to delineate the precise mechanisms
involved. Our study had several limitations, including the absence of protein-level data
corresponding to identified differentially expressed genes related to lipid metabolism with a
potential role in APA pathophysiology. In addition, we did not fully characterize the role of
oxidative stress (lipid peroxidation) in APA tissues, which warrants further investigation.
5. Conclusions
It is challenging to evaluate the tumorigenic landscape of APAs using experimental
methods. As such, it is still unclear how APA tumor adrenocortical cells maintain hy-
persecretion and cell proliferation despite a nutrient-deprived environment. We address
this knowledge gap by shedding light on the energy metabolism and tumor immune
microenvironment. Our analyses reveal that metabolic reprogramming involving a switch
to fatty acid β-oxidation and glycolysis may stimulate aldosterone production, disturb the
TME, mitigate oxidative stress, and support tumor cell survival. Therefore, we highlight
metabolic reprogramming as a putative novel mechanism in APA pathophysiology.
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